Cboe is concentrating its business around high-volume proprietary derivatives: in 2025, options and futures generated about 68% of revenue less cost of revenues, with the majority tied to exclusive index licenses and Cboe’s VIX methodology. That makes the S&P 500 license less a routine vendor contract than a foundation of the company’s core franchise.
The key change is long-term franchise security. Cboe and S&P have extended the exclusive licensing arrangement through December 31, 2051, preserving Cboe’s exclusive right to list and trade SPX options in the United States. 〔0〕 (Item 1.01; Order 1) The contract also preserves cross-licenses supporting Cboe’s volatility, BuyWrite and variance products, linking the renewal to the broader SPX/VIX ecosystem rather than to one product alone. (Item 1.01; Order 2)
The economics are a cost headwind, but management is framing it as absorbable. There is no change to 2026 royalty terms; updated per-contract fees begin January 1, 2027. 〔1〕 (Exhibit 99.1) Cboe says the 2027 reset should have a de minimis effect on net-revenue growth because volume growth, pricing opportunities and execution should outweigh it, while future adjustments will be smaller than the initial reset. 〔2〕 (Exhibit 99.1) The filing does not disclose the actual fee schedule, so the precise margin impact remains unquantified.
| Filing fact | Amount / timing | Filing location |
|---|---|---|
| Agreement term | Through Dec. 31, 2051 | Item 1.01 |
| 2026 royalty terms | No impact | Exhibit 99.1 |
| Updated royalty terms | Begin Jan. 1, 2027 | Item 1.01; Exhibit 99.1 |
| 2025 SPX options volume | 970.6 million contracts; 3.9 million ADV | Exhibit 99.2 |
| Year-over-year SPX volume growth | 25% | Exhibit 99.2 |
The renewal protects a franchise that is still expanding. SPX options traded a record 970.6 million contracts in 2025, with average daily volume of 3.9 million contracts, up 25% year over year. 〔3〕 (Exhibit 99.2) That growth gives Cboe more volume over which to spread the higher license cost, although the contract’s undisclosed thresholds and per-contract pricing mean the durability of that offset cannot be independently tested from this filing.
The agreement is more defensive than transformational today. It removes a major renewal risk for Cboe’s most important derivatives franchise and leaves room for future products, including possible tokenized options, but those innovation opportunities are permissions to pursue rather than committed revenue streams. 〔4〕 (Exhibit 99.2)
Bottom line: Cboe has secured the legal foundation of its SPX/VIX growth engine for another 25 years. The only immediate offset is a 2027 royalty increase, which management says should be small relative to continuing volume and pricing growth; the undisclosed fee details are the remaining uncertainty.
Read the original 8-K on SEC EDGAR ↗